Abstract

Introduction: The aims of the study were to document the characteristics of amyotrophic lateral sclerosis (ALS) patients in Queensland, to examine factors influencing age of onset, and survival, and to study those with early-onset (<45 years) disease and those with long (>5 years) survival. Methods: We studied subjects seen at the ALS Clinic at the Royal Brisbane and Women’s Hospital. We recorded sex, age of onset, region of onset, length of survival, presence of family history, type of disease, and evidence of cognitive involvement. We analysed the influence of these features on age of onset and survival. We analysed the features of patients with early onset of disease and patients with long survival. Results: There were 855 ALS patients (505 males) in the cohort. The age of onset was lower in males than females, in patients with a family history of ALS compared to those without, and in patients with spinal onset compared to bulbar onset. Early-onset disease was seen in 10% of patients, and had a greater proportion of males, spinal onset, and classical ALS phenotype compared to late-onset disease. Survival was shorter in females, in patients with bulbar onset, and in patients with classical ALS. Long survival was seen in 18% of patients. Patients with long survival had younger age of onset, greater proportion of males, spinal onset, and fewer patients with classical ALS. Conclusion: Our study confirms that ALS is more prevalent in males and that spinal onset is more common than bulbar onset. Males have earlier onset but longer survival. We found that overall, patients with classical ALS have worse survival than ALS variants, but some patients who were considered to have classical ALS had long survival. This study confirms the similarity of ALS in our region to ALS in other geographical regions.

© 2022 The Author(s). Published by S. Karger AG, Basel

References Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162–72. Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293–9. de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119(3):497–503. Shefner JM, Al-Chalabi A, Baker MR, Cui LY, de Carvalho M, Eisen A, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131(8):1975–8. Al-Chalabi A, Hardiman O, Kiernan MC, Chiò A, Rix-Brooks B, van den Berg LH. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016;15(11):1182–94. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7(11):603–15. Glasmacher SA, Wong C, Pearson IE, Pal S. Survival and prognostic factors in C9orf72 repeat expansion carriers: a systematic review and meta-analysis. JAMA Neurol. 2020;77(3):367–76. Rosen AD. Amyotrophic lateral sclerosis. Clinical features and prognosis. Arch Neurol. 1978;35(10):638–42. Turner MR, Barnwell J, Al-Chalabi A, Eisen A. Young-onset amyotrophic lateral sclerosis: historical and other observations. Brain. 2012;135(Pt 9):2883–91. Talman P, Duong T, Vucic S, Mathers S, Venkatesh S, Henderson R, et al. Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. BMJ Open. 2016;6(9):e012054. Gordon PH, Cheng B, Katz IB, Mitsumoto H, Rowland LP. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS. Neurology. 2009;72(22):1948–52. Quinn C, Edmundson C, Dahodwala N, Elman L. Reliable and efficient scale to assess upper motor neuron disease burden in amyotrophic lateral sclerosis. Muscle Nerve. 2020;61(4):508–11. Garg N, Park SB, Vucic S, Yiannikas C, Spies J, Howells J, et al. Differentiating lower motor neuron syndromes. J Neurol Neurosurg Psychiatry. 2017;88(6):474–83. Baumann F, Henderson RD, Ridall PG, Pettitt AN, McCombe PA. Use of Bayesian MUNE to show differing rate of loss of motor units in subgroups of ALS. Clin Neurophysiol. 2012;123(12):2446–53. Wijesekera LC, Mathers S, Parkinson MH, Ganesalingam J, Talman P, Galtrey C, et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology. 2009;72(12):1087–94. Gordon PH, Cheng B, Katz IB, Pinto M, Hays AP, Mitsumoto H, et al. The natural history of primary lateral sclerosis. Neurology. 2006;66(5):647–53. Rowland LP. Progressive muscular atrophy and other lower motor neuron syndromes of adults. Muscle Nerve. 2010;41(2):161–5. Soraru G, Ermani M, Logroscino G, Palmieri A, D' Ascenzo C, Orsetti V, et al. Natural history of upper motor neuron-dominant ALS. Amyotroph Lateral Scler. 2010;11(5):424–9. Visser J, de Jong JMBV, de Visser M. The history of progressive muscular atrophy: syndrome or disease? Neurology. 2008;70(9):723–7. Abhinav K, Stanton B, Johnston C, Hardstaff J, Orrell RW, Howard R, et al. Amyotrophic lateral sclerosis in South-East England: a population-based study. The South-East England register for Amyotrophic Lateral Sclerosis (SEALS Registry). Neuroepidemiology. 2007;29(1–2):44–8. Chio A, Borghero G, Pugliatti M, Ticca A, Calvo A, Moglia C, et al. Large proportion of amyotrophic lateral sclerosis cases in Sardinia due to a single founder mutation of the TARDBP gene. Arch Neurol. 2011;68(5):594–8. Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118–30. McCluskey G, Duddy W, Haffey S, Morrison K, Donaghy C, Duguez S. Epidemiology and survival trends of motor neurone disease in Northern Ireland from 2015 to 2019. Eur J Neurol. 2022;29(3):707–14. Beghi E, Logroscino G, Chio A, Hardiman O, Mitchell D, Swingler R, et al. The epidemiology of ALS and the role of population-based registries. Biochim Biophys Acta. 2006;1762(11–12):1150–7. Liu T, Shen D, Yang X, Cui B, Tai H, Wang Z, et al. Early onset but long survival and other prognostic factors in Chinese sporadic amyotrophic lateral sclerosis. J Clin Neurosci. 2019;69:74–80. Oliveira Santos M, Gromicho M, Pinto S, De carvalho M. Clinical characteristics in young-adult ALS - results from a Portuguese cohort study. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(7–8):620–3. Huisman MHB, de Jong SW, van Doormaal PTC, Weinreich SS, Schelhaas HJ, van der Kooi AJ, et al. Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry. 2011;82(10):1165–70. Liu MS, Cui LY, Fan DS, Chinese ALS Association. Age at onset of amyotrophic lateral sclerosis in China. Acta Neurol Scand. 2014;129(3):163–7. Santos MO, Gromicho M, Pinto S, de Carvalho M. Very late-onset amyotrophic lateral sclerosis in a Portuguese cohort. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7–8):619–22. Logroscino G, Traynor BJ, Hardiman O, Chio A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81(4):385–90. Talbot K. Clinical tool for predicting survival in ALS: do we need one? J Neurol Neurosurg Psychiatry. 2016;87(12):1275. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Incidence and prevalence of ALS in Ireland, 1995–1997: a population-based study. Neurology. 1999;52(3):504–9. McCombe PA, Garton FC, Katz M, Wray NR, Henderson RD. What do we know about the variability in survival of patients with amyotrophic lateral sclerosis? Expert Rev Neurother. 2020;20(9):921–41. Del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, Van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology. 2003;60(5):813–9. Pupillo E, Messina P, Logroscino G, Beghi E, SLALOM Group. Long-term survival in amyotrophic lateral sclerosis: a population-based study. Ann Neurol. 2014;75(2):287–97. Testa D, Lovati R, Ferrarini M, Salmoiraghi F, Filippini G. Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(4):208–12. Turner MR, Parton MJ, Shaw CE, Leigh PN, Al-Chalabi A. Prolonged survival in motor neuron disease: a descriptive study of the King’s database 1990–2002. J Neurol Neurosurg Psychiatry. 2003;74(7):995–7. Grad LI, Rouleau GA, Ravits J, Cashman NR. Clinical spectrum of Amyotrophic Lateral Sclerosis (ALS). Cold Spring Harb Perspect Med. 2017;7(8):a024117. Van den Berg-Vos RM, Visser J, Kalmijn S, Fischer K, de Visser M, de Jong V, et al. A long-term prospective study of the natural course of sporadic adult-onset lower motor neuron syndromes. Arch Neurol. 2009;66(6):751–7. Yoon BN, Choi SH, Rha JH, Kang SY, Lee KW, Sung JJ. Comparison between flail arm syndrome and upper limb onset amyotrophic lateral sclerosis: clinical features and electromyographic findings. Exp Neurobiol. 2014;23(3):253–7. Wei Q, Chen X, Zheng Z, Guo X, Huang R, Cao B, et al. The predictors of survival in Chinese amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(3–4):237–44. Weil C, Zach N, Rishoni S, Shalev V, Chodick G. Epidemiology of amyotrophic lateral sclerosis: a population-based study in Israel. Neuroepidemiology. 2016;47(2):76–81. Gao M, Liu N, Li XM, Chao LW, Lin HQ, Wang Y, et al. Epidemiology and factors predicting survival of amyotrophic lateral sclerosis in a large Chinese cohort. Chin Med J. 2021;134(18):2231–6. Wolf J, Safer A, Wöhrle JC, Palm F, Nix WA, Maschke M, et al. Factors predicting one-year mortality in amyotrophic lateral sclerosis patients - data from a population-based registry. BMC Neurol. 2014;14(1):197. Gregory JM, Fagegaltier D, Phatnani H, Harms MB. Genetics of amyotrophic lateral sclerosis. Curr Genet Med Rep. 2020;8(4):121–31. Xu Z, Alruwaili ARS, Henderson RD, McCombe PA. Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis: frequency of abnormality and effect on survival. J Neurol Sci. 2017;376:16–23. Drory VE, Artmonov I. Earlier onset and shorter survival of amyotrophic lateral sclerosis in Jewish patients of North African origin a clue to modifying genetic factors? J Neurol Sci. 2007;258(1–2):39–43. Chio A, Calvo A, Moglia C, Mazzini L, Mora G; PARALS study group. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82(7):740–6. Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10(5–6):310–23. de Jongh AD, van Eijk RPA, Peters SMB, van Es MA, Horemans AMC, van der Kooi AJ. Incidence, prevalence, and geographical clustering of motor neuron disease in The Netherlands. Neurology. 2021;96(8):E1227–36. Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. Amyotrophic lateral sclerosis in olmsted county, Minnesota, 1925 to 1998. Neurology. 2002;59(2):280–2. Chiò A, Mora G, Calvo A, Mazzini L, Bottacchi E, Mutani R, et al. Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology. 2009;72(8):725–31. Bae JS, Sawai S, Misawa S, Kanai K, Isose S, Shibuya K, et al. Effects of age on excitability properties in human motor axons. Clin Neurophysiol. 2008;119(10):2282–6. Dean G, Elian M. Motor neuron disease and multiple sclerosis mortality in Australia, New Zealand and South Africa compared with England and Wales. J Neurol Neurosurg Psychiatry. 1993;56(6):633–7. Phua CS, Ng A, Brooks C, Harrington Z, Vedam H, Huynh T, et al. Prevalence and factors associated with advanced care directives in a motor neuron disease multidisciplinary clinic in Australia. Postgrad Med J. 2021;97(1151):566–70. Haaxma CA, Bloem BR, Borm GF, Oyen WJG, Leenders KL, Eshuis S, et al. Gender differences in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(8):819–24. Reekes TH, Higginson CI, Ledbetter CR, Sathivadivel N, Zweig RM, Disbrow EA. Sex specific cognitive differences in Parkinson disease. NPJ Parkinsons Dis. 2020;6(1):7. Agarwal S, Highton-Williamson E, Caga J, Matamala JM, Dharmadasa T, Howells J, et al. Primary lateral sclerosis and the amyotrophic lateral sclerosis-frontotemporal dementia spectrum. J Neurol. 2018;265(8):1819–28. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602–11. Govaarts R, Beeldman E, Kampelmacher MJ, van Tol MJ, van den Berg LH, van der Kooi AJ, et al. The frontotemporal syndrome of ALS is associated with poor survival. J Neurol. 2016;263(12):2476–83. Trojsi F, D'Alvano G, Bonavita S, Tedeschi G. Genetics and sex in the pathogenesis of Amyotrophic Lateral Sclerosis (ALS): is there a link? Int J Mol Sci. 2020;21(10):3647. Fernández-Santiago R, Sharma M, Mueller JC, Gohlke H, Illig T, Anneser J, et al. Possible gender-dependent association of vascular endothelial growth factor (VEGF) gene and ALS. Neurology. 2006;66(12):1929–31. Fontana A, Marin B, Luna J, Beghi E, Logroscino G, Boumédiene F, et al. Time-trend evolution and determinants of sex ratio in Amyotrophic Lateral Sclerosis: a dose–response meta-analysis. J Neurol. 2021;268(8):2973–84. Gargiulo-Monachelli GM, Sivori M, Meyer M, Sica REP, De Nicola AF, Gonzalez-Deniselle MC. Circulating gonadal and adrenal steroids in amyotrophic lateral sclerosis: possible markers of susceptibility and outcome. Horm Metab Res. 2014;46(6):433–9. Yerdelen D, Koç F, Sarica Y. The effects of gender and age on motor unit number estimation in a normal population. Acta Neurol Belg. 2006;106(1):5–8. Kodama L, Gan L. Do microglial sex differences contribute to sex differences in neurodegenerative diseases? Trends Mol Med. 2019;25(9):741–9. Lopez-Lee C, Kodama L, Gan L. Sex differences in neurodegeneration: the role of the immune system in humans. Biol Psychiatry. 2022;91(1):72–80. Nordander C, Ohlsson K, Balogh I, Hansson GA, Axmon A, Persson R, et al. Gender differences in workers with identical repetitive industrial tasks: exposure and musculoskeletal disorders. Int Arch Occup Environ Health. 2008;81(8):939–47. Peters TL, Kamel F, Lundholm C, Feychting M, Weibull CE, Sandler DP, et al. Occupational exposures and the risk of amyotrophic lateral sclerosis. Occup Environ Med. 2017;74(2):87–92. McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gend Med. 2010;7(6):557–70. Chiò A, Moglia C, Canosa A, Manera U, D’Ovidio F, Vasta R, et al. ALS phenotype is influenced by age, sex, and genetics: a population-based study. Neurology. 2020;94(8):e802–10. Manjaly ZR, Scott KM, Abhinav K, Wijesekera L, Ganesalingam J, Goldstein LH, et al. The sex ratio in amyotrophic lateral sclerosis: a population based study. Amyotroph Lateral Scler. 2010;11(5):439–42. Bunina TL. [On intracellular inclusions in familial amyotrophic lateral sclerosis]. Zh Nevropatol Psikhiatr Im S S Korsakova. 1962;62:1293–9. Martin LJ, Price AC, Kaiser A, Shaikh AY, Liu Z. Mechanisms for neuronal degeneration in amyotrophic lateral sclerosis and in models of motor neuron death (Review). Int J Mol Med. 2000;5(1):3–13. Okamoto K, Mizuno Y, Fujita Y. Bunina bodies in amyotrophic lateral sclerosis. Neuropathology. 2008;28(2):109–15. Jankovska N, Matej R. Molecular pathology of ALS: what we currently know and what important information is still missing. Diagnostics. 2021;11(8):1365. Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009;65(Suppl 1):S3–9. Shellikeri S, Karthikeyan V, Martino R, Black SE, Zinman L, Keith J, et al. The neuropathological signature of bulbar-onset ALS: a systematic review. Neurosci Biobehav Rev. 2017;75:378–92. Miller RG, Mitchell JD, Moore DH. Riluzole for Amyotrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND). Cochrane Database Syst Rev. 2012;2012(3):CD001447. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157(11):1015–22. Henning F, Heckmann JM, Naidu K, Vlok L, Cross HM, Marin B. Incidence of motor neuron disease/amyotrophic lateral sclerosis in South Africa: a 4-year prospective study. Eur J Neurol. 2021;28(1):81–9. Gros-Louis F, Gaspar C, Rouleau GA. Genetics of familial and sporadic amyotrophic lateral sclerosis. Biochim Biophys Acta. 2006;1762(11–12):956–72. Lee JR-J, Annegers JF, Appel SH. Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci. 1995;132(2):207–15. Millul A, Beghi E, Logroscino G, Micheli A, Vitelli E, Zardi A. Survival of patients with amyotrophic lateral sclerosis in a population-based registry. Neuroepidemiology. 2005;25(3):114–9. Murphy M, Quinn S, Young J, Parkin P, Taylor B. Increasing incidence of ALS in Canterbury, New Zealand: a 22-year study. Neurology. 2008;71(23):1889–95. Yates E, Rafiq MK. Prognostic factors for survival in patients with amyotrophic lateral sclerosis: analysis of a multi-centre clinical trial. J Clin Neurosci. 2016;32:51–6. Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y. Amyotrophic lateral sclerosis. A study of its presentation and prognosis. J Neurol. 1985;232(5):295–300. Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve. 2002;25(5):709–14. van den Berg-Vos RM, Visser J, Franssen H, de Visser M, de Jong JM, Kalmijn S, et al. Sporadic lower motor neuron disease with adult onset: classification of subtypes. Brain. 2003;126(Pt 5):1036–47. Kornitzer J, Abdulrazeq HF, Zaidi M, Bach JR, Kazi A, Feinstein E, et al. Differentiating flail limb syndrome from amyotrophic lateral sclerosis. Am J Phys Med Rehabil. 2020;99(10):895–901. Talman P, Forbes A, Mathers S. Clinical phenotypes and natural progression for motor neuron disease: analysis from an Australian database. Amyotroph Lateral Scler. 2009;10(2):79–84. Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88(7):540–9. Zakharova MN, Abramova AA. Lower and upper motor neuron involvement and their impact on disease prognosis in amyotrophic lateral sclerosis. Neural Regen Res. 2022;17(1):65–73. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Samarelli V, Lamberti P, et al. Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based study. J Neurol Sci. 2006;250(1–2):45–9. Byrne S, Walsh C, Lynch C, Bede P, Elamin M, Kenna K, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82(6):623–7. Eisen A, Mezei MM, Stewart HG, Fabros M, Gibson G, Andersen PM. SOD1 gene mutations in ALS patients from British Columbia, Canada: clinical features, neurophysiology and ethical issues in management. Amyotroph Lateral Scler. 2008;9(2):108–19. Juneja T, Pericak-Vance MA, Laing NG, Dave S, Siddique T. Prognosis in familial amyotrophic lateral sclerosis: progression and survival in patients with glu100gly and ala4val mutations in Cu, Zn superoxide dismutase. Neurology. 1997;48(1):55–7. Mehta PR, Jones AR, Opie-Martin S, Shatunov A, Iacoangeli A, Al Khleifat A, et al. Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias. J Neurol Neurosurg Psychiatry. 2019;90(3):268–71. Kato M, Aoki M, Ohta M, Nagai M, Ishizaki F, Nakamura S, et al. Marked reduction of the Cu/Zn superoxide dismutase polypeptide in a case of familial amyotrophic lateral sclerosis with the homozygous mutation. Neurosci Lett. 2001;312(3):165–8. Zinman L, Liu HN, Sato C, Wakutani Y, Marvelle AF, Moreno D, et al. A mechanism for low penetrance in an ALS family with a novel SOD1 deletion. Neurology. 2009;72(13):1153–9. Giess R, Holtmann B, Braga M, Grimm T, Müller-Myhsok B, Toyka KV, et al. Early onset of severe familial amyotrophic lateral sclerosis with a SOD-1 mutation: potential impact of CNTF as a candidate modifier gene. Am J Hum Genet. 2002;70(5):1277–86. Mateen FJ, Carone M, Sorenson EJ. Patients who survive 5 years or more with ALS in Olmsted County, 1925–2004. J Neurol Neurosurg Psychiatry. 2010;81(10):1144–6. Byrne S, Heverin M, Elamin M, Bede P, Lynch C, Kenna K, et al. Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: a population-based case-control cohort study of familial and sporadic amyotrophic lateral sclerosis. Ann Neurol. 2013;74(5):699–708. O’Brien M, Burke T, Heverin M, Vajda A, McLaughlin R, Gibbons J, et al. Clustering of neuropsychiatric disease in first-degree and second-degree relatives of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2017;74(12):1425–30. Hu WT, Shelnutt M, Wilson A, Yarab N, Kelly C, Grossman M, et al. Behavior matters-cognitive predictors of survival in amyotrophic lateral sclerosis. PLoS One. 2013;8(2):e57584. Montuschi A, Iazzolino B, Calvo A, Moglia C, Lopiano L, Restagno G, et al. Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. J Neurol Neurosurg Psychiatry. 2015;86(2):168–73. Alruwaili AR, Pannek K, Coulthard A, Henderson R, Kurniawan ND, McCombe P. A combined tract-based spatial statistics and voxel-based morphometry study of the first MRI scan after diagnosis of amyotrophic lateral sclerosis with subgroup analysis. J Neuroradiology. 2018;45(1):41–8. Hardiman O, Al-Chalabi A, Brayne C, Beghi E, van den Berg LH, Chio A, et al. The changing picture of amyotrophic lateral sclerosis: lessons from European registers. J Neurol Neurosurg Psychiatry. 2017;88(7):557–63. Logroscino G, Traynor BJ, Hardiman O, Chio’ A, Couratier P, Mitchell JD, et al. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry. 2008;79(1):6–11. Rooney J. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. Nat Rev Neurol. 2011;7(10):538. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, et al. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2008;79(1):33–7. Article / Publication Details

First-Page Preview

Received: June 16, 2022
Accepted: December 22, 2022
Published online: December 30, 2022

Number of Print Pages: 18
Number of Figures: 9
Number of Tables: 6

ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)

For additional information: https://www.karger.com/NDD

Figures Tables